GCLLSG trial results to be presented at the 2016 ASH Annual Meeting

(1:25)

Ongoing studies by the German CLL study group (GCLLSG)

(2:38)

Overview of the CLLR3 trial of obinutuzumab

(1:39)

Highlights from ICML 2017: The CLL2-BAG study

(1:37)

Overview of the CLL2-BIG trial

(49)

CLL2-GIVe trial: investigating chemotherapy-free treatment of CLL

(1:11)

Role of chemotherapy in CLL management

(22:8)

Clinical trials of non-chemotherapy-containing therapies by the German CLL Study Group

(2:36)

Hallek Interview Part 3: Clinical Trials in CLL

(22:44)

Upcoming CLL trials on treatment options

(1:44)

Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab

(49)

Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trial

(45)

Lymphoma Hub Satellite Symposium 2019 | CLL - chemotherapy-free regimens - Michael Hallek

(10:46)

An overview of iwCLL 2017 meeting in New York by Prof. Michael Hallek

(1:33)

Data From the GLISTEN Clinical Trial for Primary Biliary Cholangitis

(7:46)

Clinical Trials Go Digital

(1:50)

GCLP and The Trial Facility Management

(3:32)

CLL Horizons 2016: Clinical Trial Uptake and Availability. Dr Arnon Kater

(27:47)